Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.

ABSTRACT:

Background

Meningioma is the most common primary intracranial tumor in adults. A subset of these tumors recur and invade the brain, even after surgery and radiation, resulting in significant disability. There is currently no standard-of-care chemotherapy for meningiomas. As genomic DNA methylation profiling can prognostically stratify these lesions, we sought to determine whether any existing chemotherapies might be effective against meningiomas with high-risk methylation profiles.

Methods

A previously published dataset of meningioma methylation profiles was used to screen for clinically significant CpG methylation events and associated cellular pathways. Based on these results, patient-derived meningioma cell lines were used to test candidate drugs in vitro and in vivo, inc

SUBMITTER: Youngblood MW 

PROVIDER: S-EPMC10013641 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature